• Relapsed/Refractory Follicular Lymphoma Part 1 — A Roundtable Discussion on the Selection and Sequencing of Therapy

  • 2025/04/22
  • 再生時間： 40 分
  • ポッドキャスト

Relapsed/Refractory Follicular Lymphoma Part 1 — A Roundtable Discussion on the Selection and Sequencing of Therapy

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics:

    • Overview of Bispecific Antibodies for the Treatment of Relapsed/Refractory (R/R) Follicular Lymphoma (FL) (0:00)
    • Clinical Data Available with Mosunetuzumab for R/R FL (1:54)
    • Clinical Data Available with Epcoritamab for R/R FL (4:54)
    • Clinical Data Available with Odronextamab for R/R FL (6:53)
    • Clinical Considerations in Selecting Among Available Bispecific Antibodies for R/R FL (8:34)
    • Practical Considerations in the Administration of Bispecific Antibodies (15:21)
    • The Role of Vaccinations in the Prevention of Infections for Patients Receiving Bispecific Antibodies (18:34)
    • Ongoing Clinical Trials Evaluating Bispecific Antibodies for FL (21:34)
    • Case: A man in his late 60s with refractory FL who received mosunetuzumab monotherapy (24:24)
    • Case: A woman in her late 50s with relapsed FL who received third-line epcoritamab monotherapy (30:14)
    • Case: A man in his late 80s with a long-standing history of FL who received odronextamab in combination with a second novel bispecific antibody (33:48)

    CME information and select publications
    続きを読む 一部表示

あらすじ・解説

Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics:

  • Overview of Bispecific Antibodies for the Treatment of Relapsed/Refractory (R/R) Follicular Lymphoma (FL) (0:00)
  • Clinical Data Available with Mosunetuzumab for R/R FL (1:54)
  • Clinical Data Available with Epcoritamab for R/R FL (4:54)
  • Clinical Data Available with Odronextamab for R/R FL (6:53)
  • Clinical Considerations in Selecting Among Available Bispecific Antibodies for R/R FL (8:34)
  • Practical Considerations in the Administration of Bispecific Antibodies (15:21)
  • The Role of Vaccinations in the Prevention of Infections for Patients Receiving Bispecific Antibodies (18:34)
  • Ongoing Clinical Trials Evaluating Bispecific Antibodies for FL (21:34)
  • Case: A man in his late 60s with refractory FL who received mosunetuzumab monotherapy (24:24)
  • Case: A woman in her late 50s with relapsed FL who received third-line epcoritamab monotherapy (30:14)
  • Case: A man in his late 80s with a long-standing history of FL who received odronextamab in combination with a second novel bispecific antibody (33:48)

CME information and select publications
続きを読む 一部表示

Relapsed/Refractory Follicular Lymphoma Part 1 — A Roundtable Discussion on the Selection and Sequencing of Therapyに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。